Juno Therapeutics (JUNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2017 | 09-2017 | 06-2017 | 03-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -437,106 | -301,070 | -182,937 | -82,197 | -245,580 |
| Depreciation Amortization | 23,632 | 15,652 | 9,027 | 3,338 | 14,186 |
| Income taxes - deferred | -6,016 | -4,242 | -2,456 | -1,332 | -10,617 |
| Accounts receivable | -623 | -21,048 | 2,937 | 4,462 | -12,968 |
| Accounts payable and accrued liabilities | 46,900 | 45,164 | 40,016 | 27,972 | 2,238 |
| Other Working Capital | 113,971 | 98,935 | 45,686 | 1,058 | -25,052 |
| Other Operating Activity | 34,209 | 34,440 | -4,167 | -7,229 | 87,984 |
| Operating Cash Flow | $-225,033 | $-132,169 | $-91,894 | $-53,928 | $-189,809 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -710,745 | -419,087 | -254,742 | -104,799 | -750,344 |
| PPE Investments | -60,924 | -56,903 | -42,991 | -21,152 | -56,246 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -74,575 |
| Sale Of Investment | 703,459 | 546,896 | 405,167 | 195,807 | 969,720 |
| Investing Cash Flow | $-68,210 | $70,906 | $107,434 | $69,856 | $88,555 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 10,804 | 10,804 | 10,804 | N/A | N/A |
| Debt Repayment | -161 | -92 | -21 | N/A | -369 |
| Common Stock Issued | 327,522 | 312,531 | 4,534 | 1,930 | 51,786 |
| Common Stock Repurchased | N/A | 0 | 0 | N/A | -10,073 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -4,562 |
| Financing Cash Flow | $338,165 | $323,243 | $15,317 | $1,930 | $36,782 |
| Exchange Rate Effect | -32 | -34 | -54 | -45 | -35 |
| Beginning Cash Position | 187,891 | 187,891 | 187,891 | 187,891 | 252,398 |
| End Cash Position | 232,781 | 449,837 | 218,694 | 205,704 | 187,891 |
| Net Cash Flow | $44,890 | $261,946 | $30,803 | $17,813 | $-64,507 |
| Free Cash Flow | |||||
| Operating Cash Flow | -225,033 | -132,169 | -91,894 | -53,928 | -189,809 |
| Capital Expenditure | -60,924 | -56,903 | -42,991 | -21,152 | -56,246 |
| Free Cash Flow | -285,957 | -189,072 | -134,885 | -75,080 | -246,055 |